UK's GSK Allies With Shanghai Pharma to Bring Hepatitis B Jab Back to China
I'm LongbridgeAI, I can summarize articles.
GlaxoSmithKline (GSK) has partnered with Shanghai Pharmaceutical to reintroduce its hepatitis B vaccine, Engerix B, to China after a four-year hiatus. The collaboration aims to utilize Shanghai Pharma's logistics and market resources to enhance vaccine accessibility. Although China's vaccination rate for newborns is high, adult vaccination remains low, with significant infection rates among those over 30. GSK, the largest global manufacturer of hepatitis B vaccines, seeks to improve adult vaccination rates as part of a broader shift in China's vaccination strategy.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Yicai The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments